glp-1 agonist medications Agonists: A Comprehensive Overview Holding GLP-1 Agonists Prior to

& Reaven, P

doi: 10.1093/humupd/dmp008 142 MoranLJTassoneECBoyleJBrennanLHarrisonCLHirschbergALet al

A 2024 study led by Wang, Volkow, and colleagues examined two cohorts totaling over 682,000 individuals with either obesity or type 2 diabetes and found the risk of new alcohol use disorder diagnoses was about 50% lower among those taking semaglutide compared to other anti-obesity or diabetes medications (Wang et al., 2024a)

These data come from Cosmos, a dataset created in collaboration with a community of Epic health systems representing more than 300 million patient records from 1,900 hospitals and more than 42,000 clinics from all 50 U.S